|
|
B16-F0
|
|
Biosafety Level: |
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
adherent |
|
|
Mus musculus (mouse)
|
|
|
Spindle shaped
|
|
|
Organ: skin Strain: C57BL/6J Disease: melanoma |
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
transfection host (Roche FuGENE® Transfection Reagents Nucleofection technology from Lonza) |
|
|
Yes
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
|
|
Protocol: - Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
- Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:10 is recommended Medium Renewal: Every 2 to 3 days |
|
|
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002 recommended serum:ATCC 30-2020 |
|
|
22151: Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35: 218-224, 1975. PubMed: 1109790 22191: Fidler IJ, et al. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A. Cancer Res. 36: 3608-3615, 1976. PubMed: 953987 22192: Fidler IJ, Bucana C. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Cancer Res. 37: 3945-3956, 1977. PubMed: 908034 22243: Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895, 1977. PubMed: 887927 22424: Fidler IJ. Immune stimulation-inhibition of experimental cancer metastasis. Cancer Res. 34: 491-498, 1974. PubMed: 4812256 23224: Briles EB, Kornfeld S. Isolation and metastatic properties of detachment variants of B16 melanoma cells. J. Natl. Cancer Inst. 60: 1217-1222, 1978. PubMed: 418183 23362: . . Nat. New Biol. 242: 148-149, 1973. |